NCT02368951 2017-07-12Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)BayerPhase 1 Terminated20 enrolled